Atopic Dermatitis in Adulthood Linked to Increased Risk for VTE
Researchers sought to evaluate patients with atopic dermatitis for risk of incident venous thromboembolism (deep vein thrombosis and/or pulmonary embolism).
Diagnosis & Disease Information
Prenatal Antibiotic Exposure Increases Risk for Childhood Atopic Dermatitis
A retrospective study of nearly 1.3 million babies evaluated whether maternal use of antibiotics during pregnancy may increase childhood risk for atopic dermatitis.
Solace Cream Now Available OTC for Eczema Treatment
Resilia Pharmaceuticals has announced the relaunch of Solace Cream for the treatment of signs and symptoms of eczema.
Cibinqo Approved for Adolescents With Moderate to Severe Atopic Dermatitis
The approval was based on data from previous studies that included 124 adolescent patients, as well as the phase 3 JADE TEEN study.
Tapinarof Cream Eases Atopic Dermatitis in Patients as Young as 2 Years
Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.
Mode of Delivery May Be a Risk Factor for Early Childhood Atopic Dermatitis
A cohort study of mother and child pairs investigates the association between mode of delivery and atopic dermatitis in children 5 years of age and younger.
Consistent Results Observed With Topical Roflumilast in Second Atopic Dermatitis Trial
The INTEGUMENT-2 trial included patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area.
OTC Moisturizers Are Cost-Effective Treatment for Atopic Dermatitis
Theoretical annual costs of OTC moisturizer are compared with costs of atopic dermatitis; Medicaid coverage is also reviewed.
AAD Releases Guideline to Increase Awareness on Comorbidities in Atopic Dermatitis
A new American Academy of Dermatology (AAD) guideline describes available evidence on comorbidities associated with atopic dermatitis (AD) in adults.
Dupixent Approved for Atopic Dermatitis in Younger Pediatric Patients
The approval was based on data from a phase 3 study that evaluated Dupixent added to low potency topical corticosteroids in children aged 6 months to 5 years with uncontrolled moderate to severe atopic dermatitis.
- Loading...
Loading...
Next post in Pediatrics
Loading... 
Loading...